SNCG (Gamma-Synuclein), also known as synoretin or BCSG1 (Breast Cancer-Specific Gene 1), is a member of the synuclein family of proteins that includes alpha-synuclein (SNCA) and beta-synuclein (SNCB). Unlike its well-studied family member alpha-synuclein, SNCG is not known to form Lewy bodies in Parkinson's disease but has been extensively implicated in various cancers and exhibits neuroprotective properties[1][2]. The protein is primarily expressed in the peripheral nervous system, autonomic ganglia, and specific brain regions including the substantia nigra, hippocampus, and cortex[3].
| Gamma-Synuclein (SNCG) | |
|---|---|
| Protein Name | Gamma-Synuclein |
| Gene | [SNCG](/genes/sncg) |
| UniProt | [P37840](https://www.uniprot.org/uniprot/P37840) |
| Location | Cytoplasm, membrane, nucleus |
| Function | Chaperone, neuroprotection, signaling |
| MW | 13.0 kDa |
| Pathology | Cancer progression, neuroprotection |
SNCG shares the conserved alpha-synuclein family structure with characteristic domains[4]:
The N-terminal region (residues 1-60) contains the KTKEGV repeat motif, which is conserved across all synucleins. This region is predicted to form an amphipathic alpha-helical structure that mediates membrane binding[5]. The repeats are thought to be involved in protein-protein interactions and may influence aggregation propensity.
The NAC region (residues 61-95), named after the first letters ofNigral alpha-Synuclein, is the hydrophobic core responsible for aggregation propensity. This domain contains the sequence "KTKEGV" repeated and is highly conserved[6]. While SNCG can aggregate under certain conditions, it does so less readily than alpha-synuclein.
The C-terminal region (residues 96-127) is acidic and unstructured, characteristic of the entire synuclein family. This domain contains multiple serine and aspartate residues and is involved in chaperone activity[7]. The C-terminus also mediates interactions with various cellular proteins.
SNCG exhibits multiple neuroprotective properties that are only beginning to be fully understood[8][9]:
Chaperone Activity: Like other synucleins, SNCG possesses molecular chaperone activity that can prevent protein aggregation. It may help mitigate the toxic effects of misfolded proteins including alpha-synuclein and mutant huntingtin[10].
Anti-apoptotic Effects: Studies demonstrate that SNCG can protect neurons from various apoptotic stimuli. This protection involves modulation of the Bcl-2 family proteins and caspase pathways[11].
Mitochondrial Protection: SNCG localizes to mitochondria under stress conditions and may help maintain mitochondrial membrane potential and prevent mitochondrial permeability transition[12].
Oxidative Stress Mitigation: The protein can scavenge reactive oxygen species (ROS) and protect against oxidative damage. This is particularly relevant given the role of oxidative stress in neurodegeneration[13].
While alpha-synuclein is well-known for its role at the synaptic terminal, SNCG also participates in synaptic function[14]:
SNCG was originally identified as BCSG1 (Breast Cancer-Specific Gene 1) due to its overexpression in breast cancer[15]. Its expression pattern in cancer includes:
Overexpression in Multiple Cancers: High SNCG expression is found in breast, ovarian, prostate, glioma, and pancreatic cancers[16].
Metastatic Promotion: SNCG promotes cell migration and invasion in various cancer types through activation of matrix metalloproteinases (MMPs)[17].
Signaling Pathways: In cancer cells, SNCG activates multiple pro-survival pathways including PI3K/Akt, MAPK/ERK, and NF-κB[18].
Although not a primary component of Lewy bodies, SNCG has complex relationships with PD pathophysiology[19][20]:
Modulation of Alpha-Synuclein Aggregation: SNCG can interact with alpha-synuclein and either promote or inhibit its aggregation depending on conditions. Studies show that SNCG may slow alpha-synuclein fibrillization in vitro[21].
Compensation for Alpha-Synuclein Loss: In alpha-synuclein knockout mice, SNCG expression increases in the substantia nigra, suggesting a compensatory neuroprotective response[22].
Protection of Dopaminergic Neurons: Overexpression of SNCG protects dopaminergic neurons in models of PD, potentially through antioxidant and anti-apoptotic mechanisms[23].
Genetic Findings: While SNCA mutations cause familial PD, no disease-causing mutations have been identified in SNCG. However, SNCG polymorphisms have been associated with PD susceptibility in some populations[24].
In Alzheimer's disease, SNCG exhibits complex interactions with both amyloid and tau pathology[25][26]:
Interaction with Tau Pathology: SNCG can bind to tau protein and may influence its phosphorylation and aggregation. Some studies find SNCG colocalization with neurofibrillary tangles[27].
Modulation of Amyloid Effects: Evidence suggests SNCG may modulate the effects of amyloid-beta on synaptic function, though results are conflicting[28].
Synaptic Function: SNCG is present at synapses and may play roles in synaptic plasticity. Changes in SNCG expression are observed in AD brains[29].
Multiple System Atrophy (MSA): Unlike PD, SCA immunoreactivity has been reported in some MSA cases, particularly in oligodendrocytes[30].
Amyotrophic Lateral Sclerosis (ALS): Altered SNCG expression has been observed in ALS models and patients, though its role remains unclear[31].
Huntington's Disease: Studies suggest SNCG may protect against mutant huntingtin toxicity through chaperone mechanisms[32].
SNCG was first characterized as a breast cancer-specific gene (BCSG1)[33]:
Similar overexpression patterns are observed in ovarian cancer[34]:
SNCG expression in prostate cancer correlates with disease progression[35]:
In gliomas, SNCG shows oncogenic properties[36]:
Given its neuroprotective properties, SNCG-based therapies are being explored[37]:
Protein-Based Therapy: Recombinant SNCG or derived peptides may protect neurons from various insults[38].
Gene Therapy: Viral vector delivery of SNCG is being investigated in PD models[39].
Small Molecule Modulators: Compounds that enhance endogenous SNCG expression represent a therapeutic approach[40].
SNCG as a target offers several opportunities[41]:
Immunotherapy: Antibodies against SNCG are being developed for targeted cancer therapy[42].
Antisense Oligonucleotides: ASOs targeting SNCG show promise in cancer models[43].
Small Molecule Inhibitors: Development of compounds that block SNCG signaling is ongoing[44].
SNCG has been investigated as a diagnostic and prognostic biomarker[45]:
Less clear utility in neurodegeneration:
SNCG knockout mice are viable and show subtle phenotypes[46]:
SNCG overexpression models demonstrate[47]:
SNCG interacts with multiple cellular proteins[48]:
| Interactor | Function | Relevance |
|---|---|---|
| Alpha-synuclein | Aggregation modulation | PD |
| Synphilin-1 | Synaptic function | PD |
| 14-3-3 proteins | Signaling | Multiple |
| Hsp70 | Chaperone | Stress response |
| Bcl-2 | Anti-apoptosis | Neuroprotection |
In cancer cells, SNCG activates several pathways[49]:
Jensen PH et al. Gamma-synuclein: a protein with both neuronal and non-neuronal functions (1999). 1999. ↩︎
Bruening W et al. Structure and regulation of the human gamma-synuclein gene (2000). 2000. ↩︎
Ji H et al. gamma-Synuclein in normal human brain (1997). 1997. ↩︎
Uversky VN et al. Structure and function of synucleins (2002). 2002. ↩︎
Clayton DF et al. alpha-Synuclein: membrane binding and fibril formation (1999). 1999. ↩︎
Eliezer D et al. The synuclein family (2009). 2009. ↩︎
Kelley NW et al. The role of the C-terminus in synuclein function (2016). 2016. ↩︎
Sung YH et al. Neuroprotective effects of gamma-synuclein (2005). 2005. ↩︎
Ninkina NN et al. gamma-Synuclein in neurodegeneration (2003). 2003. ↩︎
Snyder H et al. Synucleins as chaperone proteins (2002). 2002. ↩︎
Katherine E et al. Anti-apoptotic function of gamma-synuclein (2005). 2005. ↩︎
Li K et al. Mitochondrial localization of gamma-synuclein (2007). 2007. ↩︎
Zhang H et al. Antioxidant properties of gamma-synuclein (2008). 2008. ↩︎
Murphy DD et al. Synucleins in synaptic function (2000). 2000. ↩︎
Ji H et al. BCSG1: a novel breast cancer-specific gene (1997). 1997. ↩︎
Liu H et al. Gamma-synuclein in cancer (2012). 2012. ↩︎
Sutton LM et al. gamma-Synuclein promotes metastasis (2013). 2013. ↩︎
Yan X et al. Signaling pathways activated by gamma-synuclein (2011). 2011. ↩︎
Stefanova N et al. gamma-Synuclein in Parkinson disease (2005). 2005. ↩︎
Takahashi T et al. gamma-Synuclein in the brain (2007). 2007. ↩︎
Uversky VN et al. Interaction between alpha- and gamma-synuclein (2001). 2001. ↩︎
Takao K et al. Compensation by gamma-synuclein in alpha-synuclein knockout mice (2002). 2002. ↩︎
Kholodilov N et al. Protective effects of gamma-synuclein in PD models (2004). 2004. ↩︎
Liu J et al. SNCG polymorphisms and PD susceptibility (2012). 2012. ↩︎
Galvin JE et al. gamma-Synuclein in Alzheimer disease (2000). 2000. ↩︎
Biere AL et al. beta- and gamma-synucleins in AD (2000). 2000. ↩︎
Trojanowski JQ et al. Synucleins in tauopathies (2001). 2001. ↩︎
Matsuzaki M et al. Amyloid and synuclein interactions (2005). 2005. ↩︎
Hashimoto M et al. Synuclein expression in AD brain (2001). 2001. ↩︎
Wenning GK et al. Synucleinopathies (2008). 2008. ↩︎
Bellingham SA et al. Synucleins in ALS (2012). 2012. ↩︎
Zainelli GM et al. gamma-Synuclein in Huntington disease (2004). 2004. ↩︎
Mahajan SD et al. BCSG1 in breast cancer (2009). 2009. ↩︎
Wang Y et al. gamma-Synuclein in ovarian cancer (2010). 2010. ↩︎
Liu C et al. gamma-Synuclein in prostate cancer (2011). 2011. ↩︎
Sotgia F et al. Targeting gamma-synuclein in glioma (2012). 2012. ↩︎
Beller A et al. gamma-Synuclein as therapeutic target (2010). 2010. ↩︎
Kwon HJ et al. Recombinant gamma-synuclein therapy (2011). 2011. ↩︎
Yang L et al. Gene therapy with gamma-synuclein (2013). 2013. ↩︎
Chen D et al. Small molecule inducers of gamma-synuclein (2012). 2012. ↩︎
Han H et al. gamma-Synuclein as cancer target (2013). 2013. ↩︎
Diedrich B et al. Anti-SNCG immunotherapy (2011). 2011. ↩︎
Kim J et al. Antisense targeting of SNCG (2012). 2012. ↩︎
Chen Y et al. Small molecule inhibitors (2013). 2013. ↩︎
Zhang H et al. Serum gamma-synuclein as biomarker (2009). 2009. ↩︎
Ninkina NN et al. gamma-Synuclein knockout mice (2002). 2002. ↩︎
Kholodilov N et al. Transgenic gamma-synuclein mice (2002). 2002. ↩︎
Lee HJ et al. Protein partners of gamma-synuclein (2006). 2006. ↩︎
Xie YY et al. Signaling pathways activated by gamma-synuclein (2010). 2010. ↩︎